Atlanta-based startup EarliTec Diagnostics, in a move to revolutionize the state of autism diagnosis and care, has secured $21.5 million in a Series B funding round co-led by Nexus NeuroTech Ventures and Venture Investors. This significant capital injection aims to expand the company’s innovative diagnostic system that utilizes AI to detect autism in children as young as 16 months old, providing a swift and accurate alternative to traditional assessment methods.
According to the Centers for Disease Control and Prevention (CDC), autism affects one in 36 children in the United States, underscoring the critical need for early diagnosis and intervention. EarliTec’s breakthrough FDA-authorized approach involves a concise 12-minute test where children watch short videos and social interactions on a tablet screen while AI algorithms analyze their eye movements. The system identifies patterns in how children engage with the content, distinguishing those with autism from their typically developing peers.
CEO Tom Ressemann highlighted the urgency of early detection, emphasizing that timely diagnosis significantly enhances developmental outcomes. Traditional assessments, often lasting three to four hours, are plagued by lengthy waitlists, whereas EarliTec’s streamlined test is designed to integrate seamlessly into clinicians’ workflows, whether at home, in clinics, or schools.
With the newly raised capital, EarliTec plans to expand commercialization efforts, aiming to broaden the age range of diagnosable children and enhance assessment and treatment options. Ressemann, drawing from his extensive experience in the medical device industry, acknowledged the challenge of fundraising in the autism healthcare sector, historically less attractive to investors. However, he noted a shifting tide in investor sentiment, citing increased awareness and prevalence statistics driving interest.
The Autism Impact Fund’s recent closure of a $60 million fund, exceeding its $50 million target, underscores this growing momentum in the autism-focused healthcare space. Ventures like Divergent Ventures and Nexus NeuroTech Ventures are actively supporting neurodiversity initiatives, reflecting a broader industry trend towards addressing autism-related challenges.
Ressemann’s personal connection to the cause, rooted in his family’s journey with autism, adds depth to EarliTec’s mission. Reflecting on the evolving landscape of autism awareness, Ressemann emphasized the transformative impact of heightened recognition on investment and innovation. Regarding VC interest, Ressemann also added that “Where there is a large unmet need there is often interest to get into that.”
